Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson CEO alleges FTC shared confidential info in attempt to broker deal for generic Provigil

This article was originally published in Scrip

Executive Summary

An unusual court fight is ongoing between the CEO of Watson Pharmaceuticals, Paul Bisaro, and the US Federal Trade Commission. Mr Bisaro has alleged that the FTC shared confidential information with a competitor, Apotex, and improperly attempted to broker a business deal between the two generic drug makers for the genericisation of the US market for Cephalon's sleep disorder drug Provigil (modafinil), all the while undercutting a reverse-payment settlement that Watson and other generics firms made with Cephalon in 2005. Mr Bisaro also claims that the FTC is improperly attempting to subpoena him.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts